Bibliographical noteFunding Information:
This study was supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID), and the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Bethesda, MD, Public Health Service grant/cooperative agreements U54-AI082973 (PI: M.J.C.), and U54-NS064808 and U01-TR001263 (PI: J.P. Krischer) and R13-AI094943 (PI: M.J.C.), and the Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, NIAID, NIH. The Primary Immune Deficiency Treatment Consortium (PIDTC) is a part of the Rare Diseases Clinical Research Network of ORDR, NCATS. The collaborative work of the PIDTC with the Pediatric Blood and Marrow Transplant Consortium (PBMTC) is supported by the U54 grants mentioned above along with support from the PBMTC Operations Center by the St Baldrick's Foundation and grant/cooperative agreement U10-HL069254 (PI: M.A. Pulsipher) from both the National Heart, Lung and Blood Institute (NHLBI) and the National Cancer Institute (NCI), NIH. The collaborative work of the PIDTC with the Center for International Blood and Marrow Transplant Research (CIBMTR) is supported by grant/cooperative agreement U24-CA76518 (PI: M.M. Horowitz) from the NCI, the NHLBI, and the NIAID; grant/cooperative agreement U01-HL069294 from the NHLBI; NCI contracts HHSH250201200016C and HHSH234200637015C with the Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services; and grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research. The content and opinions expressed are solely the responsibility of the authors and do not represent the official policy or position of the NIAID, ORDR, NCATS, NIH, HRSA, or any other agency of the US government.